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Senescence is a physiological process that causes a permanent cell cycle arrest
(Hayflick L, Exp. Cell Res,1961). Different physiological processes or stimuli lead the
cell to the entrance into this state (Lozano B, et al. Nat Rev Chem, 2019). In this
context, senescence chemical inducers, such as Palbociclib, have recently reached
clinics for the treatment of tumors in combination with conventional therapies
(Sutherland RL, et al. Breast Cancer Res. ,2009; Finn RS, et al. Breast Cancer Res.,
2009). However, recent research has revealed the negative consequences that the
persistence of senescent cells in the body has on the development of tumors and the
appearance of metastases (Wieland E, et al. Cancer Cell, 2017; Milanovic M, et al.
Nature 2017; Parrinello S, et al. J. Cell Sci. 2005). Therefore, the design of new
treatment strategies requires efficient elimination of remaining senescent cells
(senolysis) upon therapeutic senoinduction (Kirkland JL, et al. J. Am. Geriatr., 2017;
Zhu Y, et al. Aging Cell, 2016).
Here, we report a combination of senogenesis (senoinduction with palbociclib) with
nanoformulated targeted senolysis (encapsulated navitoclax) in triple negative
orthotopic breast cancer mice model. Our results show that treatment of TNBC with
palbociclib and further elimination of senescent cells with encapsulated navitoclax in
galacto-oligosaccharide capped MSNs has benefit in tumour development, reduces
metastases formation and has the additional benefit of diminishing navitoclax negative
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systemic toxicity that impedes its clinical translation. This aggressive mice model
nearly recapitulates all the characteristics of the human TNBC, making the results
obtained from this study particularly relevant in terms of clinical translation.
We believe that our findings will attract a broad readership and could lead to the
therapeutic targeting of senescent cells for improving chemotherapy outcome in breast
cancer treatment.
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Abstract: Senescence induction produces a stable cell cycle arrest of cancer cells, arresting
tumor growth and promoting immune clearance. However, incomplete clearance of
senescent cells may favour tumor dormancy and recurrence, plausibly limiting the
positive effects of these drugs in the long term. An approach to overcome this situation
is the combination of senescence induction with the subsequent elimination of
senescent cells. In this work, the antitumor efficacy of a combination therapy involving
senogenesis and targeted senolysis, in an orthotopic immunocompetent model of the
highly aggressive 4T1 triple negative breast cancer, has been explored. Senogenesis
is induced with palbociclib, whereas senolysis is achieved with nano-encapsulated
navitoclax. Treatment with palbociclib and further elimination of senescent cells with
encapsulated navitoclax has demonstrated to delay or even prevent tumor growth,
reduces metastases and has the additional benefit of diminishing the systemic toxicity
of navitoclax. Conceivably, this principle could be applied to other senescence-
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Abstract: Senescence induction produces a stable cell cycle arrest of cancer cells, arresting 
tumor growth and promoting immune clearance. However, incomplete clearance of senescent 
cells may favour tumor dormancy and recurrence, plausibly limiting the positive effects of these 
drugs in the long term. An approach to overcome this situation is the combination of senescence 
induction with the subsequent elimination of senescent cells. In this work, the antitumor efficacy 
of a combination therapy involving senogenesis and targeted senolysis, in an orthotopic 





































































        
 
 2 
explored. Senogenesis is induced with palbociclib, whereas senolysis is achieved with nano-
encapsulated navitoclax. Treatment with palbociclib and further elimination of senescent cells 
with encapsulated navitoclax has demonstrated to delay or even prevent tumor growth, reduces 
metastases and has the additional benefit of diminishing the systemic toxicity of navitoclax. 





Cellular senescence can be defined as a state of stable cell cycle arrest in response to stressful 
stimuli.[1,2] As senescent cells become cell-cycle arrested, senescence has appeared as a desirable 
outcome in tumor treatment. Thus, several senescence-inducing or senescence-reinforcement 
drugs have been developed, including telomerase activity inhibitors, tumor suppressor gene re-
activators or cyclin dependent kinase (CDKs) inhibitors.[3,4] In fact, CDK4/6 inhibitors 
abemaciclib,[5] palbociclib [6] and ribociclib [7] have been recently approved by the Food and 
Drug Administration (FDA) for the treatment of estrogen receptor (ER)-positive metastatic 
breast cancer in combination with anti-hormonal therapy, showing the best progression-free 
survival (PFS) results obtained to date.[8–10] Specifically, palbociclib is an oral highly specific 
inhibitor that blocks CDK4- and CDK6- cyclin D kinase activity at very low concentrations.[6,11] 
Moreover, given the pre-clinical results obtained [6] and after several clinical trials,[9,12–17] 
palbociclib is currently prescribed as a combination therapy with either letrozole or fulvestrant 
for the treatment of ER+/Her2- advanced breast cancer patients and is in clinical trials for the 
treatment of triple negative breast cancer (TNBC) patients overexpressing the androgen receptor 




































































        
 
 3 
most aggressive and with poorer prognosis of the breast cancer subtypes with few treatment 
options. 
Despite the clinical potential of senescence inducers, it is now well-established that the role of 
senescent cells can be either beneficial or detrimental regarding their implication in age-related 
diseases or cancer,[18] phenomenon known as antagonistic pleiotropy.[19] When cell damage takes 
place, during cancer or aging, senescent cells initiate a sequence of processes involving the 
immune system that culminates in senescent cells clearance and tissue regeneration. 
Nevertheless, this beneficial process can be corrupted, particularly in aged tissues when the 
immune system may become impaired. When senescent cells cannot be efficiently eliminated, 
their accumulation aggravates tissue dysfunction, causes ineffective tissue regeneration and 
contributes to several diseases.[20–24] The antagonistic pleiotropy character of senescence is also 
reflected in the role of the secretory associated senescence phenotype (SASP) as it is thought to 
participate in the clearance of pre-malignant cells, reinforcing the senescence state and 
participating in tissue remodelling and repair; but it can also contribute to tumor progression by 
stimulating phenotypes associated with aggressive cancer cells, providing an ideal niche for 
cancer cells proliferation or contributing to the epithelial-to-mesenchymal transition.[1,21,23] 
Senescence can therefore be a double-edged sword by either suppressing or promoting tumor 
development.[24–27] For all these reasons, if senescent cells remain in the organism and 
accumulate, they can become a potential risk for future carcinogenesis and metastasis.[28–30] 
Therefore, in relation to cancer, the long-term improvement of chemotherapy and senescence-
inducing treatments inevitably involves the elimination of senescent cells.[31]  
There are two main therapeutic approaches to attenuate senescence negative effects: senolysis 




































































        
 
 4 
Regarding senolysis, a selective and universal method for the elimination of senescent cells 
would be a potentially useful therapy, but no such senolytic drugs are yet approved. 
Nevertheless, a number of small molecules are known to have senolytic effect both in vitro and 
in vivo models.[33] Among them, navitoclax is a potent specific inhibitor of the anti-apoptotic 
proteins Bcl-2, Bcl-w and Bcl-xL.[34] The survival of senescent cells is highly dependent on the 
elevated levels of the BCL-2 family of anti-apoptotic factors, and this makes them hypersensitive 
to apoptosis induced by Bcl-2 inhibitors.[34–37] Of note, the Bcl2 family inhibitor navitoclax, one 
of the most potent senolytic drugs, has some toxic side effects that prevent the FDA from 
approving its clinical use. In particular, its major dose-limiting toxicity is thrombocytopenia, an 
effect derived from the inhibition of Bcl-xL.[38,39]  
From another point of view, the design of nanomaterials as drug carriers with improved 
pharmacokinetics, bioavailability and biodistribution has revolutionized the field of controlled 
drug delivery systems in the last years. Among different nanocarriers, mesoporous silica 
nanoparticles (MSNs) have proven to be excellent scaffolds to develop multifunctional 
nanodevices for advanced medical applications, thanks to their advantageous characteristics such 
as homogeneous porosity, inertness, high loading capacity and easy surface functionalization. 
Moreover, MSNs can be gated with different molecular ensembles resulting in nanodevices 
showing “zero” release that can be opened on-command upon the application of specific 
physical, chemical or biochemical stimuli.[40–42] MSNs have been specially used for cancer 
treatment as they can passively accumulate in tumors due to the enhanced permeability and 
retention (EPR) effect. Moreover and due to their cargo release triggering ability, they can direct 
the protected cargo to specific targeted sites, thus reducing associated side effects in healthy 




































































        
 
 5 
tested in several senescence-related diseases models such as dyskeratosis congenital,[46,47] 
chemotherapy-treated xenograft tumors or lung fibrosis.[48] 
We report herein a combination of senogenesis with targeted senolysis in an orthotopic and 
immunocompetent triple negative breast cancer model. Senogenesis is induced with the CDK4/6 
inhibitor palbociclib, and senolysis is achieved with navitoclax encapsulated in MSNs capped 
with a galacto-oligosaccharide. Similar nanoparticles loaded with the dye indocyanine green are 
also used to trace senescence in vivo. We show that treatment of TNBC with palbociclib and 
further elimination of senescent cells with encapsulated navitoclax has benefit in tumor 
development, reduces metastases formation and has the additional added benefit of diminishing 




2.1. Palbociclib induces senescence in 4T1 triple negative breast cancer cells  
The 4T1 murine breast cancer cell line has a triple negative highly aggressive profile and the in 
vivo model recapitulates many aspects of the human disease.[49–52] The relevance of immunity in 
the antitumoral response, and particularly upon senescence induction, makes fundamental 
performing studies of tumor evolution in the presence of an intact immune system.[53,54] For this 
reason, we considered the use of this orthotopic immunocompentent breast cancer murine model 
to develop in vivo studies of senoinduction and senolysis.  
Only some subtypes of triple negative breast tumors respond properly to treatment with CDK4/6 
inhibitors.[55] Thus, we first determined the sensitivity of 4T1 TNBC cell line to treatment with 
palbociclib. We found that treatment with 5µM palbociclib produced the appearance of canonical 




































































        
 
 6 
enzyme (SA-βGal) [56,57] (Figure 1A) that was accompanied by an increase in cell size and 
higher number of intracellular vesicles, in agreement to morphological features described for 
senescent phenotype.[1,20,32] Reduced immunostaining of the Ki67 proliferation marker, 
indicative of cell cycle arrest, was also detected (Figure 1B) together with a progressive 
decrease in the phosphorylation of the retinoblastoma protein (pRb) (Figure 1C). To further 
confirm cycle arrest in 4T1 palbociclib-treated cell cultures, clonogenic assays were also 
performed. To this end, the same number of control and senescent cells were initially seeded in 
culture plates and, one week later, the increase of cell number was estimated by crystal violet 
staining. 4T1 cell cultures treated with palbociclib showed less staining, indicative of decreased 
cellular proliferation and consistent with cellular arrest (Figure 1D). All together, these results 
confirmed that senescence was efficiently induced by the CDK4/6 inhibitor palbociclib in the 
4T1 triple negative murine breast cancer cell line. 
 
2.2. Senolysis in 4T1 breast cancer senescent cells 
Senescent cells are highly dependent on various pro-survival factors. In particular, the 
dependence on the anti-apoptotic protein Bcl-xL has been reported in different cell lines.[58] We 
wondered if overexpression of this anti-apototic Bcl-2 family protein member was also taking 
place in 4T1-palbociclib treated cells. To address this question we analysed changes in protein 
expression of Bcl-xL as a consequence of palbociclib treatment. The levels of the anti-apoptotic 
member increased significantly as a consequence of senescence induction (Figure 2A). This 
increase was accompanied by an increment in the expression of pro-apoptotic BH3-only protein 




































































        
 
 7 
cells”, which show a high dependence on anti-apoptotic proteins for survival and become highly 
sensitive to BH3 mimetics drugs such as navitoclax.[59,60]  
Inhibition of Bcl-2 anti-apoptotic proteins by free navitoclax (Nav) was then explored as a 
strategy to selectively induce cell death in 4T1-senecent cells. First, mitochondrial functionality 
upon treatment of 4T1 cells with free navitoclax was analysed by flow cell cytometry using the 
membrane-permeable dye JC-1.[61] JC-1 dye accumulates in the mitochondria in a potential 
dependent manner, shifting the fluorescence emission maximum from green to red. A decrease in 
the population of cells with a high red/green fluorescence ratio is indicative of a loss of 
mitochondrial functionality. Palbociclib-induced 4T1 senescent and control cells were treated 
with navitoclax and mitochondrial membrane potential changes were analyzed. Senescent cells 
showed a reduced mitochondrial membrane potential when compared with non-treated cells 
(Figure 2B), which is in agreement with other reported studies with senescent cells.[62–64] Upon 
treatment with navitoclax, a further decrease in mitochondrial potential was observed (Figure 
2B) and it was accompanied by a selective cell death induction (Figure 2C) only in the 4T1-
senescent cultures. In fact, the IC50 of navitoclax was 0.3µM for senescent cultures, while this 
drug concentration did not produce cell death in normal cultures that presented a considerable 
higher IC50 concentration. Senolytic activity at the IC50 was also confirmed either by crystal 
violet cell cytotoxicity assays (Figure 2D) and by flow cytometry, quantifying dead cells that 
exposed phosphatidyl-serine to the outer plasma membrane leaflet in an Annexin V FITC 
binding assay (Figure 2E). Both studies confirmed the selectivity of navitoclax for inducing cell 
death in senescent cells. Finally, a caspase 3/7 activity detection assay confirmed that the cell 
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On the basis of the mesoporous silica nanoparticles advantages, navitoclax was encapsulated in 
MSNs capped with a hexa-galacto-oligosaccharide molecule obtaining the loaded nanoparticles 
Gal·NP(Nav) (Figure 3A). Considering that senescent cells are characterized by high levels of 
lysosomal β-galactosidase activity (SA-βGal), the galacto-oligosaccharide acts as a “molecular 
gate” that is expected to be hydrolysed in senescent cells by the action of this senescence-
associated β-galactosidase activity. Similar capped nanoparticles were loaded with the 
fluorescent dye indocyanine green (ICG), referred to as Gal·NP(ICG).  
TEM images of the nanoparticles showed spherical particles of ca. 80-100nm in which the 
channels of the MCM-41 matrix were visualized as alternate black and white stripes or as a 
honeycomb porous structure (Figure 3B, Figure S3). N2 adsorption-desorption studies 
confirmed the presence of uniform cylindrical mesoporous in the starting MSNs, with a pore size 
of 2.8 nm and a total specific surface of 1091 m2 g-1 (Table S1). Moreover, a significant decrease 
in the adsorbed N2 volume and surface area was observed in the loaded Gal·NP(ICG) 
nanoparticles (57 m2 g-1) which confirmed cargo loading inside the pores (Figure S4). From 
dynamic light scattering (DLS) measurements (Figure S5), the hydrodynamic diameter of the 
starting MSNs and the final Gal·NP(ICG) were determined to be 183 nm and 376 nm, 
respectively (Table S2), with a single population distribution which indicated the good 
dispersion of the particles. This increase in the hydrodynamic diameter, as well as the increase in 
zeta potential values, was consistent with the external functionalization of the nanoparticles with 
the galacto-oligosaccharide, and also occurred in Gal·NP(Nav) (301 nm) and in the capped 
nanoparticles without cargo Gal·NP(0) (249 nm). Moreover, experiments with both 
Gal·NP(ICG) and Gal·NP(Nav)  demonstrated efficient cargo capping and a selective and 




































































        
 
 9 
capping galacto-oligosaccharide (Figure S6 and Figure 3C, respectively). For Gal·NP(Nav) 
nanoparticles, termogravimetrical and HPLC studies indicated that there were 141.4mg of 
galactoologisaccharide per gram of solid, and that 60 mg of navitoclax were delivered per gram 
of nanoparticles in the presence of β-galactosidase.  
Gal·NP(ICG) nanoparticles were validated in the 4T1 murine breast cancer cell line by confocal 
microscopy and flow cytometry. Both studies showed that Gal·NP(ICG) released their content 
more efficiently in palbociclib-senescent cells compared to control cells after 6 or 24 hours 
(Figure 3D, Figure S7), in concordance with their high levels of β-galactosidase activity. The 
ICG probe is located in a perinuclear region consistent with the release of the drug in the 
lysosomal compartment.  In a next step, the navitoclax-loaded nanoparticles Gal·NP(Nav) were 
also tested in 4T1 cells. Treatment of control and senescent 4T1 cells with increasing 
concentrations of the nano-senolytic Gal·NP(Nav) caused a selective decrease in senescent cells 
viability with an IC50 of 0.07µM of navitoclax, which is significantly lower than that obtained 
for the free drug (0.3µM) (Figure 3E). Crystal violet staining of cells treated with Gal·NP(Nav)  
at the free navitoclax IC50 concentration confirmed the selective induction of cell death in 
senescent cells (Figure 3F). Finally biocompatibility studies with capped nanoparticles with no 
cargo, Gal·NP(0), showed that empty nanoparticles were harmless for 4T1 cells at 72h for all 
studied concentrations (Figure S8). Hence, oligosaccharide-capped nanoparticles demonstrated 
suitable to deliver ICG preferentially in palbocliclib-induced 4T1 senescent cells and navitoclax 
enhanced its senolytic activity when encapsulated, demonstrating the functionality of the 
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2.3. In vivo imaging and treatment of 4T1 triple negative breast cancer tumors 
Once demonstrated the capability of palbociclib to induce senescence in the 4T1 cellular model, 
we moved one step forward to study the combination of senogenesis (senoinduction by 
palbociclib) with targeted senolysis (using Gal·NP(Nav) and free navitoclax) in a triple negative 
orthotopic breast cancer model, aiming to improve antitumor efficacy. Studies with the dye-
loaded Gal·NP(ICG) nanoparticles were also carried out. 
Balb/cByJ female mice (4-6 weeks) were injected in the mammary pads with 4T1 cells for tumor 
formation. After one week of free tumor growth, palbociclib treatment started by daily oral 
gavage for one week (50mg/kg) (Figure 4A). Senescence induction was efficiently achieved in 
palbociclib treated animals, as inferred from the increase in SA-βGal activity that was observed 
in the tumors (Figure 4B). Senescence was also confirmed immunohistochemically in tumor 
sections, where the expression of the proliferative marker Ki67 decreased in palbociclib treated 
tumors as a consequence of cell cycle arrest associated to the senescent status (Figure 4C). 
To validate the preferential in vivo cargo delivery by the capped nanocarriers, animals were 
intraperitoneally administrated with Gal·NP(ICG)  after 1 week of palbo treatment. In vivo 
imaging studies of the probe distribution 24h post-injection clearly showed the preferential 
accumulation of the fluorescent dye in palbociclib-treated tumors (Figure 4D), with only a mild 
signal over the background observed in tumors non-treated with palbociclib but administrated 
with Gal·NP(ICG). Moreover, the biodistribution of the nanoparticles was studied by the 
determination of silicon in different organs by inductively coupled plasma mass spectroscopy 
(ICP-MS) (Figure 4E). Interestingly, the levels of silicon indicate that nanoparticles accumulate 
both in senescent and non-senescent tumors. Enhanced dye signal in palbociclib-treated tumors 
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the dye is strongly auto-quenched inside the capped nanoparticles).[43–45] Overall this 
demonstrated that Gal·NP(ICG)   can be of use for the detection of senescence by optical in vivo 
imaging. 
After demonstrating that oligosaccharide capped nanoparticles preferentially release the 
fluorescent dye ICG in senescent tumors, we wondered whether encapsulated senolytic 
navitoclax would also target senescent cells in vivo in the TNBC model. Three days after 4T1 
cells orthotopic injection, mice were treated with palbociclib when a visible tumor was evident 
on the mammary pads of the animals. One day after initiating palbociclib administration, either 
free navitoclax or encapsulated Gal·NP(Nav) was administered for 16 days (Figure 5A). 
Treatment efficacy and safety was monitored by measuring tumor size and body weight every 
two days.  
All groups receiving palbociclib treatment significantly reduced tumor size in comparison with 
non-palbociclib treated groups (Figure 5B). In fact, groups that were not treated with the 
CDK4/6 inhibitor (Control, Nav or Gal·NP(Nav)) reached the humane endpoint at day 15 of 
palbociclib treatment (Figure 5D). It is important to note that the senolytic treatments had no 
effect on the tumors in the absence of senogenic treatment with palbociclib. Tumor size 
reduction by palbociclib is of particular interest, as on-going clinical trials with palbociclib in 
combination with bicalutamide in triple negative breast cancer patients are focused on patients 
overexpressing the androgen receptor (AR) (Clinical Trial ID: NCT02605486).[55] Noticeably, 
the 4T1 cell line does not express the AR receptor (Figure S10), so the observed palbociclib 
antitumoral activity in vivo in the 4T1 TNBC model suggest the potential application of this drug 
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Concerning co-treatments with the senescence inductor palbociclib plus the senolytic navitoclax, 
interestingly Gal·NP(Nav) had a therapeutic benefit in combination with palbociclib, whereas 
treatment with only Gal·NP(Nav) displayed no effect, demonstrating that the therapeutic effect 
of Gal·NP(Nav) requires the induction of senescence (Figure 5B and 5C).  Animals treated with 
palbociclib and free navitoclax died or reached human end point at day 15. 
Activation of cell death was assessed by immunofluorescence assays of active caspase 3 in tumor 
sections (Figure 5F) demonstrating that apoptosis was occurring in Gal·NP(Nav) co-treated 
tumors due to navitoclax release. In addition, all palbociclib plus Gal·NP(Nav) treated animals 
survived until the end of the experiment without relevant changes in body weight (Figure S9). In 
contrast the combination of palbociclib and free navitoclax produced  a clear decrease in animal 
survival (Figure 5D) and those animals that survived had to be euthanatized before the end point 
of the study due to an excessive weight loss (more than 10%). This is indicative of a reduction in 
navitoclax toxicity when encapsulated. Another important result to highlight was that 
Gal·NP(Nav) co-treated animals presented a reduction in the number of lung metastases when 
compared to mice only treated with palbociclib (Figure 5E). This is remarkable as metastases 
formation is one of the most common consequences in human breast cancer. Collectively, we 
conclude that encapsulation of the senolytic drug navitoclax produces a benefit in tumor 
development and metastases formation, with the added benefit of reducing drug negative side-
effects.  
 
3. Discussion and conclusion 
Senescence has been traditionally considered an evolutionary strategy to avoid tumor 
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reached clinics. However, as knowledge has advanced the double-edged sword role of 
senescence in cancer evolution has been evidenced. Recent reports have shown that traditional 
chemotherapeutics, such as doxorubicin and radiotherapy, cause senescence in tumors.[3] This 
therapy induced senescence could have both positive and negative consequences for patients. On 
one hand, senescent cells are eliminated by macrophages, and contribute to the generation of 
anti-tumoral immune responses; while on the other hand they are a source of inflammatory 
signalling molecules that shape the microenvironment towards pro-carcinogenesis, supporting 
tumor cell spreading. In terms of benefits, a seminal study showed that genetic clearance of 
p16INK4A - expressing senescent cells increases survival of mice with tumors at the time of 
death.[65] Since then, it has been demonstrated that a number of diseases are associated with the 
presence of senescent cells and that their elimination is beneficial in mouse models. However, it 
has not been properly addressed how the dual behaviour of senescence could be affecting those 
treatments that actively produce senescence in tumors and that are currently in clinical use, such 
as the CDK4/6 inhibitor palbociclib. Considering these circumstances there is a clear potential 
for treatment improvement that needs to be addressed. In this work we demonstrate that a 
combination of senogenesis (senoinduction with palbociclib) with nanoformulated targeted 
senolysis (encapsulated nanvitoclax) in triple negative orthotopic breast cancer mice model 
improves antitumor efficacy, metastases reduction and reduce navitoclax negative toxicity. This 
aggressive mice model nearly recapitulates all the characteristics of the human TNBC, making 
the results obtained from this study particularly relevant in terms of clinical translation. 
The encapsulated nanodevice consists of spherical mesoporous silica nanoparticles of ca. 100 nm 
diameter, loaded with navitoclax and capped with galacto-oligosaccharides that prevent cargo 
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nanoparticles have proved suitable for selectively deliver certain cargos in senescent cells. 
Selective opening and delivery is based on the high levels of lysosomal β-galactosidase activity 
present in senescent cells in diseased and damaged tissues. β-galactosidase hydrolysis of the cap 
induces pore opening and payload release. On the basis of the mesoporous silica nanoparticles 
advantages, we also prepared capped nanoparticles loaded with the fluorescent dye indocyanine 
green, Gal·NP(ICG). 
In terms of palbociclib treatment we demonstrate that senescence was efficiently induced by the 
CDK4/6 inhibitor palbociclib in the 4T1 triple-negative murine breast cancer cell line that do not 
express the androgen receptor. As stated above, on-going clinical trials with palbociclib in triple 
negative breast cancer patients are today focussed on patients overexpressing the AR, so our 
result suggests that there is still room for the potential application of palbociclib to novel 
subgroups of TNBC patients. Cellular studies also demonstrate that Gal·NP(ICG) nanoparticles 
released their content more efficiently in palbociclib-senescent cells compared to control cells, in 
concordance with their high levels of β-galactosidase activity. Moreover, treatment of 4T1 cells 
with Gal·NP(Nav) induce a selective decrease in senescent cells viability which is significantly 
lower than that found for the free navitoclax. Moreover, capped nanoparticles with no cargo are 
harmless for 4T1 cells at 72h. 
In vivo imaging studies of the Gal·NP(ICG) distribution 24h post-injection clearly show the 
preferential accumulation of fluorescent dye in palbociclib-treated tumors, which is corroborated 
by the determination of silicon in different organs by inductively coupled plasma mass 
spectroscopy. This demonstrates our nanoparticles can be of use for the detection of senescence 
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Moreover, the nanoparticles loaded with navitoclax (i.e Gal·NP(Nav)) have a therapeutic benefit 
in combination with palbociclib. Encapsulation of navitoclax in the nanoparticles contributes to 
significantly reduce navitoclax toxicity. Animals treated with the combination palbociclib plus 
Gal·NP(Nav) survive to the in vivo experiment without relevant changes in body weight, 
whereas mice treated with palbociclib and free navitoclax showed a decrease in animal survival 
and weight loss. Besides, animals treated with palbociclib and Gal·NP(Nav) present a decreased 
number of lung metastases when compared to mice only treated with palbociclib, which is a 
remarkable result in terms of long survival prognosis.  
Reduction of tumor size observed upon senolysis could be explained in different terms: i) the 
immune surveillance system is overloaded as consequence of continuous palbociclib induced 
senescence, and the senolytic drug contributes to help to senescent cells elimination; ii) 
chronically induced senescent cells actively evade the immune system and senolysis represents 
an alternative contribution to their elimination; iii) senolysis acts as an adjuvant therapy 
activating immune surveillance and favoring senescent cells elimination. However, the extent to 
which these mechanisms contribute to tumor reduction remains to be elucidated. Further studies 
addressing these questions would contribute to outline new antitumor strategies. 
 
4. Experimental section 
Chemicals and nanoparticles synthesis 
Tetraethyl orthosilicate (98%), n-cetyltrimethylammonium bromide (CTAB) (≥99%), sodium 
hydroxide (NaOH) (≥98%), (3-aminopropyl)trimethoxysilane (APTES) (95%), anhydrous 
acetonitrile, anhydrous dichloromethane, indocyanine green (ICG), were purchased from Sigma-
Aldrich. Galactan (from potato) was purchased from Carbosynth, and navitoclax was purchased 
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Synthesis of the mesoporous silica nanoparticles (NPs scaffolds) was performed following 
reported procedures, as previously described by Muñoz-Espín et al,[48] with some modifications. 
For ICG-loaded nanoparticles, 0.4g of NPs scaffolds were added to a stirred solution of 
indocyanine green (ICG) (0.019g, 0.024 mmol) in 90mL of water. After 24h, the mixture was 
filtered and dried under vacuum. Nanoparticles were the functionalized by addition of APTES 
(0.4mL, 1.8 mmol) to a suspension of 0.3g of loaded scaffolds in 11mL of anhydrous MeCN. 
After 5.5h stirring at room temperature, the solid was isolated by filtration and dried under 
vacuum. For coating the scaffolds, 0.3g of functionalized nanoparticles were suspended in a 
solution of β(1,4)‐galacto‐hexasaccharide (0.74g, 1.4 mmol) and 40mL of water. After stirring 
for 21h at room temperature, the final product, referred to as Gal·NP(ICG) was filtered, washed 
with plenty of water and dried under vacuum. The same APTES functionalization and β(1,4)‐
galacto‐hexasaccharide coating steps were performed to obtain the capped nanoparticles without 
load, referred to as Gal·NP(0).  
For navitoclax-loaded nanoparticles, 0.3g of NPs scaffolds were added to a solution of 
navitoclax (0.23g, 0.24 mmol) in 10mL of anhydrous dichloromethane, and the suspension was 
stirred at room temperature for 24h. Then, in the functionalization step, APTES (0.42mL, 1.8 
mmol) was added to the suspension, and the stirring was kept for a further 5.5h. The obtained 
product was isolated by filtration under vacuum. For coating the functionalized navitoclax-
loaded scaffolds, the same procedure as in the synthesis of Gal·NP(ICG)  was followed. The 
final product referred to as Gal·NP(Nav) was isolated by filtration and washed with plenty of 
water and cold EtOH.  
All the synthesized solids were stored in a desiccant at room temperature. A schematic 
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Gal·NP characterization methods 
Powder X-ray diffraction (PXRD), transmission electron microscopy (TEM), N2 adsorption-
desorption isotherms, thermogravimetric analysis (TGA), UV‐visible and emission spectroscopy 
techniques were used were employed for materials characterization. PXRD measurements were 
performed on a Seifert 3000TT diffractometer using CuKα radiation at low angles (1.3 < 2θ < 
8.3, with steps of 0.04 degrees and 3 seconds for step) and high angles (35 < 2θ < 80, with steps 
of 0.04 degrees and 1 second for step). Thermogravimetric analyses were carried out on a 
TGA/SDTA 851e Mettler Toledo equipment, using an oxidant atmosphere (air, 80 mL/min) with 
a heating program consisting on a heating rate of 10°C/min from 393K to 1273K and an 
isothermal heating step at this temperature for 30 min. For high resolution TEM imaging, 
samples were deposited on copper grids covered with carbon film provided by Electron 
Microscopy Sciences, and were recorded with 200 KV in a JEOL JEM-2100F microscope 
equipped with a X ray detector. N2 adsorption-desorption isotherms were recorded on a 
Micromeritics TriStar II Plus automated analyser. Samples were previously degassed at 40°C in 
vacuum overnight and measurements were performed at 77K. The specific surface areas were 
calculated from the adsorption data in the low pressures range using the BET model. Pore size 
was determined by following the BJH method. Dynamic light scattering (DLS) measurements 
were carried out in a Malvern Zetasizer Nano ZS. UV‐visible spectroscopy was carried out with 
a Lambda 35 UV/Vis spectrometer (Perkin‐Elmer Instruments), and fluorescence spectroscopy 
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Cargo release studies from Gal·NP(Nav) 
4mg of Gal·NP(Nav) were suspended in 10mL of water at pH 4.5, stirred and this volume was 
separated into two suspensions of 5mL. Then, aliquots of 200µL were taken and 300µL of ethyl 
acetate were added to each one. The mixture was stirred for 1min, the ethyl acetate was taken, 
centrifuged and measured by UV-visible spectroscopy. Then, 5mg of β‐galactosidase from 
Aspergillus oryzae were added to one of the aliquots, and, after certain time (1h, 3h, 5h...) 300µL 
of ethyl acetate was added to each one, stirred for 1 min, organic phase was taken, centrifuged 
and cargo released in organic phase was measured. Cargo release studies from Gal·NP(ICG) 
were also performed, and are resumed in Figure S6. 
 
Cell lines 
Cell line 4T1 (mus musculus mammary gland) was obtained from American Type Culture 
Collection (ATCC) and maintained in Dulbecco’s modified Eagle’s medium (DMEM, Sigma) 
supplemented with 10% fetal bovine serum (FBS), at 37ºC humidified atmosphere with 5% 
CO2. For senescence induction, medium was supplemented with palbociclib (#S1116, 
Selleckchem) at 5µM for 7 days.  
 
β-galactosidase activity staining 
Both 4T1 cultured cells and whole tissues (frozen tumor sections) were stained for SA-βGal 
detection using the Senescence β-galactosidase Staining Kit (#9860, Cell Signaling). Cells were 
fixed in 4% PFA at room temperature for 15 min, and staining was performed by following the 
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sections were fixed in 4% PFA for 45-60 min at room temperature, washed with PBS and 
incubated for 5 hours with the staining solution at 37ºC with no CO2.  
 
Immunoblotting 
Cells were washed with PBS and lysed with 150-200µL of lysis buffer (25mM Tris HCl pH 7.5, 
SDS 1%, 1mM EDTA pH 8 and protease inhibitors) supplemented with fosfatase inhibitor for 
pRb analysis. Cells were then harvested, passed through a 25G needle several times and boiled 
for 10min. Protein quantification was performed using the BCA method. Lysates were resolved 
in 6-12% acrylamide/bis-acrylamide gels, transferred to nitrocellulose membranes (#10600003, 
Acefesa) and immunoblotted following standard procedures.  
Primary antibodies: Phospho-Rb (Ser807/811) (D20B12) antibody (#8516, #9308, Cell 
Signaling); AR antibody (#ab3590; Abcam); BCL-xL antibody (#2764, Cell Signaling); Bim 
antibody (#2819, Cell Signaling);  
Secondary antibodies: anti-Rabbit IgG peroxidase antibody (#A6154, Sigma); peroxidase 
conjugate-goat anti-Mouse IgG antibody (#A4416, Sigma).  
 
Ki67 immunofluorescence  
Cells were fixed with 4% PFA, permeabilized with 0.3% triton X-100 and blocked with 5% BSA 
for 1h. Then cells were labelled with the primary antibody solution (1% BSA, 0.3% triton X-
100) containing Ki-67 (D3B5) Rabbit (#9129, Cell Signaling), overnight at 4ºC. A following 
incubation with anti-rabbit IgG Fluor Goat 633 (#A21071, Fisher) was performed for 2h at room 
temperature. For image visualization coverslips were prepared in mounting medium and 
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Colony formation assay 
Control and senescent cells were seeded at different densities in 24-well plates and incubated in a 
CO2 incubator at 37°C for 1 week. Colonies were fixed with 4% PFA and stained with 0.05% 
crystal violet solution.  
 
BH3 profiling assay 
Control and senescent cells were treated or non-treated with free navitoclax 0.3µM for 24 hours 
and mitochondrial activity was measured using the plate-based JC-1 BH3 profiling assay 
previously described by Letai et al.66 Control and senescent cells were seeded in a 96-multiwell 
plate at a concentration of 200000 cells/well in DTEB buffer (135mM trehalose, 10mM HEPES-
KOH pH 7.5, 50mM KCl, 0.1% BSA, 5mM succinate, 0.02mM EGTA, 0.02mM EDTA in 
distilled water and pH 7.5). Once plated, 100µL of supplemented DTEB (125µM oligomycin, 
0.10mg/mL digitonin, 10µM JC1 and 50mM β-mercaptoethanol) and 2µL DMSO / 2µL BH3 
peptides / 1µL FCCP were added to each well. Mitochondrial charge was measured by JC-1 red 
fluorescence over 3 hours in a PerkinElmer Multimode Plate Reader EnsightTM.  
 
Cell viability assays  
4T1 control and senescent cells (previously one week treated with Palbociclib 5µM) were seeded 
in flat-bottom clear white p96-multiwell plate at 3500 and 7500 cells/well concentration, 
respectively. Next day free navitoclax, Gal·NP(Nav) or Gal·NP(0) treatments were added at 
different concentrations (0.03-20µM for free formulation; 0.01-2mg/mL for Gal·NP previous 
filtration – 0.45µm) and cells were incubated for 72 hours. Cell viability was measured by 
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Promega) in a PerkinElmer Life Sciences Wallac Victor2TM spectrophotometer. For colony 
formation assays cells were seeded at 35000 (control) and 75000 (senescent) cells/well and 
treated with free navitoclax 0.3µM or the equivalent Gal·NP(Nav) concentration. After 72 hours 
colonies were fixed with 4% PFA and stained with 0.05% crystal violet solution.  
 
Annexin V apoptosis assay 
For the apoptosis evaluation assays 4T1 control and senescent cells were treated, or non-treated, 
with navitoclax 0.6µM. After 72 hours of incubation, cells were labelled with Alexa 
fluoresceinisothiocyanate-conjugated Annexin V (BD Bioscience) plus propidium iodide 
according to the manufacturer’s recommendations. Samples were analysed in the cytometer 
CytoFLEX S Beckman Coulter.  
 
Cell-based caspase activation assay 
4T1 senescent cells were seeded in 6-well plate at a cellular density of 1.5 × 105 cells/mL. The 
next day cells were treated with navitoclax (1µM) and when indicated with 5µM of caspase 3 
inhibitor z-VAD-FMK (ALX-260-020; Enzo Life Sciences). 48 hours later, cells were harvested 
and S100 cytosolic extracts were obtained. Total protein (50 μg) was mixed with assay buffer 
(PBS, 10% glycerol, 0.1mM EDTA, 2 mMDTT) containing 20μM Ac-DEVD-afc substrate. 
Activity was monitored using a Victor 2 spectrofluorimeter. 
 
Confocal microscopy with Gal·NP(ICG) 
Control and senescent cells were seeded on 6-multiwell plates at a concentration of 150000 
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and cells and nanoparticles were incubated together for 6 hours and then washed with PBS in 
order to eliminate non-internalized nanoparticles. For confocal microscopy, coverslips were 
mounted and Hoechst and a plasmatic membrane dye (WGA Alexa Fluor 488 Conjugate, 
#W11261, ThermoFisher) were added for nuclei and membrane staining prior to cells 
visualization.  
 
Animal model  
Female BALB/cByJ wild type mice (28-34 days old) were purchased from Charles River 
Laboratories and maintained in ventilated racks under pathogen-free conditions at Principe 
Felipe Research Centre (Valencia, Spain), with food and water ad libitum and alternate dark and 
light cycles. All animals were treated humanely and experiments were approved by the Ethical 
Committee for Research and Animal Welfare.   
 
Tumor formation 
For each group 5 mice were used for statistical significance. Mice were anesthetized with 
isofluorane and the injection area was lightly shaved. Each animal was injected subcutaneously 
in the second lower right breast, with a cellular concentration of 0.5 million early passage 4T1 
cells resuspended in 100µL of free-serum medium. Tumor growth was controlled every two days 
using an electronic caliper, and volume (mm3) was estimated using the formula (length x 
width2)/2, were width was considered to be the shorter of two perpendicular diameters. 
Moreover, weight and animal welfare were also evaluated along all the treatments, attending to 
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Mice treatments  
Palbociclib for senescence induction was administrated by daily oral gavage (50-100 mg/kg) 
dissolved in sodium lactate 50mM at 16.5mg/mL.  
For IVIS experiments to visualize nanoparticles localization, animals started palbociclib 
treatment one week post tumoral cell injection, and was daily maintained for one more week. 
Then Gal·NP(ICG) were intraperitoneally injected (200µL of a 10mg/mL suspension) and 
animals were observed in IVIS at different time points (6-24h post injection; ʎexc 745nm, ʎem 
840 nm). Mice were finally euthanized in CO2 atmosphere and organs were also observed ex vivo 
in IVIS.  
For experiments with free or encapsulated navitoclax (#HY-10087, Medchemexpress), 
palbociclib administration began one day before starting the senolytic treatment and three days 
after 4T1 cells injection. Navitoclax was also daily administrated and maintained for 16 days, by 
oral gavage in case of free formulation (25 mg/kg, dissolved in 15%DMSO/PEG400) or by 
intraperitoneal injection (200µL of a 4 mg/mL suspension, equivalent to 2.5mg/kg of navitoclax) 
in case of Gal·NP(Nav). At the end of the treatments animals were euthanized and organs were 
extracted for posterior evaluation.  
For nanoparticles use, the corresponding nanoparticles were weighted in glass vials and 
resuspended in free-serum DMEM at the indicated concentrations, then were lightly sonicated in 
a water bath and stirred for 1 hour before administration. In vitro experimental calculations 
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Imaging by IVIS 
For in vivo and ex vivo animals or organs fluorescence imaging after Gal·NP(ICG) treatments, 
an IVIS Spectrum Imaging System (Caliper LifeSciences) was used. For in vivo visualization, 
animals were anesthetized with 4-4.5% isofluorane in the induction period, and maintained with 
2-2.5% during the scanning time. For ex vivo organs and tumors imaging, animals were 
euthanized at different time points after nanoparticles injection (6 or 24 hours) and organs were 
harvested and immediately analysed. Signal from Gal·NP(ICG) nanoparticles loaded with 
indocyanine green was detected using excitation and emission wavelengths of 745nm and 
840nm, respectively. Fluorescence quantification was performed by Living Image® 4.3.1 
software and was measured in photons per second per square centimetre per steradian 
(p/s/cm2/sr). Fluorophore release was quantified by manual drawing of regions of interest (ROIs) 
over the detected fluorescence signals in organs or tumors.  
 
Metastases quantification 
Lungs were collected after euthanasia and fixed in 4% PFA. Paraffin-embedded tissue sections 
on glass slides were processed for hematoxylin-eosin staining, and stained lung sections were 
scanned in a Leica Aperio Versa 200 equipment at 10x magnification. Metastatic 4T1 cell 
clusters were microscopically counted in different lung sections from five animals per group.  
 
Ki67 Inmunohistochemistry  
Indirect immunoperoxidase immunostaining was performed on 4% PFA-fixed paraffin-
embedded tumor samples by an automated immunostaining platform (Leica Microsistems Bond 
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and then with the corresponding secondary antibody. Slides were counterstained with 
hematoxylin, dehydrated, and coverslipped.  
 
Caspase 3 Immunofluorescence 
Tumor sections (8µm) were fixed in 4% PFA and blocked with 5% goat serum, 0.1% Triton X-
100 in PBS. Samples were labelled with caspase 3 active antibody (#9661; Cell Signaling) 
followed by anti-rabbit IgG conjugated to Alexa Fluor 488 (Life Technologies). Confocal images 
of ten different fields per sample were captured with a Leica SP8 microscope. Quantification of 
caspase 3 signal was performed evaluating the mean fluorescence value of the different fields 
using the ImageJ software analysis. 
 
Silica biodistribution 
Selected organs (lungs, liver, spleen, kidneys and tumor) were harvested and conserved for 
silicon (Si) detection. Organs were first weighted and then individually introduced in 
polytetrafluoroethylene (PTFE) bottles. 1mL of tetramethylammonium hydroxide solution 
(TMAH, #331635, Sigma) was added to each recipient, bottles were firmly closed and digestion 
was carried out for 2h at 80ºC using a digestion unit Bloc digest 20 (Selecta). After cooling, 
digested samples were diluted with milliQ water to 10 mL in polypropylene Erlenmeyer flasks, 
then filtered in 0.45µm filters (#17463443, Scharlab) and kept in polystyrene tubes until 
determination. For the analysis, 0.5mL of sample was diluted to 10mL with a solution of 2% 
nitric acid and 1% hydrochloric acid. Silicon determination was performed in an Inductively 
Coupled Plasma Mass Spectrometer System (ICP-MS) Agilent 7900 in H2 mode, using 
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ICP (#08729, Sigma), and standard solutions were digested and treated exactly the same way as 
the mice samples. Data are expressed as µg Si/g sample. 
 
Statistical analysis  
Statistical analysis of data used GraphPad Prism software. Comparisons of results between 
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Figures and legends 
 
Figure 1. Palbociclib induces senescence in 4T1 triple negative breast cancer cells.  A) β-
galactosidase activity increases in 4T1 cells treated with palbociclib. 4T1 breast cancer cells 
were treated with palbociclib 5µM for one week, and senescence induction was confirmed by a 
β-galactosidase activity staining assay (blue signal) in both control and senescent cells. B) 
Decrease in the expression of the proliferation marker Ki67 upon senescence induction with 
palbociclib. Confocal microscopy images of immunofluorescence staining of Ki67 (red). Nuclei 
were stained with Hoechst (blue). C) pRb decreases upon palbociclib treatment. 4T1 cells were 
treated with palbociclib 5µM and total protein extracts were obtained at day 2 and day 7 to 
perform western blot analysis of the phosphorylated retinoblastoma protein (pRb) (expected 
band at 110kDa). Tubulin determination was included as loading control. D) 4T1 cells treated 
with palbociclib become cell cycle arrested. Cell proliferation studies of control and one week 
palbociclib-treated 4T1 cells. Increasing cell concentrations were seeded in different 24-plate 
wells (1000, 2500, 5000, 10000, 20000 and 30000; from left to right) and were let to proliferate 
for one week. Cell cycle arrest was confirmed by crystal violet staining. Graph represents 









































































Figure 2. Navitoclax treatment induces senolysis in 4T1 palbociclib-treated cells. A) Anti-
apoptotic Bcl-xL protein is over-expressed in palbociclib treated cells. Bcl-2 protein expression 
profile in control and senescent 4T1 cells analysed by western blot (left panel). Quantification of 
the bands using Gapdh as loading control (n=4) (right panel). Values are expressed as mean ± 
SD and statistical significance was assessed by the two-tailed Student’s T-test: **p < 0.05. B) 
Navitoclax treatment produces depolarization of mitochondria from 4T1 senescent cells. Red 
fluorescence analysis of the JC-1 probe was used to measure mitochondria depolarization (n=3). 
Values are expressed as mean ± SEM and statistical significance was assessed by the two-tailed 
Student’s T-test: *p < 0.05. C) Navitoclax induces cell death in 4T1 palbociclib-treated cells: 
control and senescent cells were treated with different concentrations of navitoclax (0.005 to 
30µM) and cell viability was measured after 72 hours of treatment by luminescent ATP detection 
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were treated with navitoclax at the IC50 concentration (0.3µM) for 72 hours. E) Treatment of 
4T1 senescent cells with navitoclax induces the accumulation of annexin V positive cells. Flow 
cytometry analysis of annexin V staining in cells previously treated with navitoclax at the IC50 
concentration (0.3µM) for 72 hours. Values are expressed as mean ± SEM and statistical 
significance was assessed by the two-tailed Student’s T-test: **p < 0.05. F) Navitoclax treatment 
induces apoptosis in 4T1 senescent cells. Caspase 3/7 activity was measured upon described 
conditions. Values from three independent experiments are expressed as mean ± SD and 
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Figure 3. Gal·NP(Nav) selectively release the cargo in a β-galactosidase dependent manner. 
A) Schematic representation of the gated nanoparticles and their synthesis. Mesoporous silica 
nanoparticles are loaded with the cargo (either ICG or navitoclax). Once loaded, the 
nanoparticles are functionalized in the external surface with (3-aminopropyl)triethoxysilane. 
Finally the hexa-galacto-oligosaccharide is covalently grafted onto the outer surface of the 
nanoparticles through the formation of a hemiaminal bond. B) Representative high resolution 
TEM images of Gal·NP. Spherical nanoparticles of ca. 100nm are observed, as well as the 
honeycomb structure of the porous scaffold or the channels as black and white longitudinal 
stripes. Scale bar: 50nm (down), 100nm (up). C) Cargo release studies of Gal·NP(Nav), 
measured in absorption emission spectrometry. The graph shows the release profile of the load in 
the absence (blank) and in the presence of β-galactosidase from Aspergillus oryzae in water at 
pH 4.5 at room temperature at the indicated time points. D) Gal·NP(ICG) internalizes 
preferentially in senescent cells. Confocal analysis of control and senescent cells incubated with 
the fluorophore-loaded nanoparticles for 6 or 24 hours. Blue: Hoechst; Green: WGA Alexa Fluor 
488 Conjugate; Red: ICG. Values are expressed as mean ± SEM and statistical significance was 
assessed by the two-tailed Student’s T-test: p < 0.05. E-F) Treatment of 4T1 senescent cells with 
Gal·NP(Nav) induces cell death. Cell viability studies at different free or encapsulated 
navitoclax concentrations by i) luminescent ATP detection (left panel), or ii) crystal violet at the 









































































Figure 4. In vivo senescence induction by palbociclib and targeting with Gal·NP(ICG). A) 
Temporal scheme of palbociclib treatment in 4T1 orthotopic mice model to evaluate senescence 
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was administered by oral gavage (50mg/kg) for 7 days. Gal·NP(ICG) were intraperitoneally 
injected (100mg Gal·NP(ICG)/kg) and animals were examined in IVIS at 6 and 24 hours post-
administration to evaluate the nanoparticles localization. B) Palbociclib induces senescence in 
4T1 TNBC. β-galactosidase staining of breast tumors (blue). C) The proliferation marker Ki67 
decreases in palbociclib treated tumors. Ki67 detection by immunohistochemistry of tumor 
sections. D) Gal·NP(ICG) nanoparticles are able to selectively release the cargo in tumors of 
palbociclib-treated animals. In vivo and ex vivo analysis by IVIS spectrum imaging system. The 
upper panel shows the in vivo images from IVIS. The lower panel shows the ex vivo fluorescence 
signal in tumors and its corresponding emitted fluorescence quantification by Living Image® 
4.3.1 software. Values (n=5) are expressed as mean ± SEM and statistical significance was 
assessed by the two-tailed Student’s T-test: *p < 0.05. E) Biodistribution of the nanoparticles. 
Silicon is analysed by Inductively Coupled Plasma Mass Spectroscopy (ICP-MS). Data are 
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Figure 5. Senolysis by Gal·NP(Nav) reduces tumor size safely and effectively. A) Temporal 
scheme of palbociclib treatment in 4T1 orthotopic mice model followed by the senolytic 
treatment with free or encapsulated navitoclax. Three days after 4T1 cells injection, palbociclib 
treatment was started and daily maintained for 17 days (oral gavage, 100mg/kg). A day after 
palbociclib initiation, the senolytic treatment started and was daily maintained for 16 days (free 
navitoclax: oral gavage, 25mg/kg; Gal·NP(Nav): intraperitoneal injection, 40mg 
Gal·NP(Nav)/kg (equivalent to 2.5mg/kg of free Navitoclax).  B) Co-treatment with palbociclib 
plus Gal·NP(Nav) reduces tumor growth. Balb/cByJ female mice were orthotopically injected 
with 4T1 breast cancer cells and treated daily with vehicle or palbociclib and free navitoclax or 
Gal·NP(Nav) alone or in combination, at the indicated doses in A). For each tumor, the relative 
volume change was calculated in comparison to its baseline prior to treatment. Values (n=5) are 
expressed as mean ± SEM. C) Representative image of the tumors from section B), in which an 
ex vivo volume size comparison is observed between palbociclib treatment versus palbociclib 
combination with capped empty nanoparticles (Gal·NP(0)) or encapsulated navitoclax 
(Gal·NP(Nav)). Tumor volumes at final day 18 are expressed in mm3 as mean ± SD (n=5) and 
statistical significance was assessed by One-way ANOVA: *p < 0.05. D) Encapsulation of 
navitoclax enhances mice survival. Graph representation of animals’ survival during the 
experimental period. E) Combined palbociclib plus Gal·NP(Nav) treatment reduces lung 
metastases in 4T1 TNBC model. Metastatic 4T1 cells clusters were microscopically counted in 
different lung hematoxylin-eosin stained sections and plotted in the graph (n=5). Values are 
represented as mean ± SEM and statistical significance was assessed by One-way ANOVA: 
***p<0.05. F) Active caspase 3 is only determined in palbociclib plus Gal·NP(Nav) co-treated 
tumors. Representative images of the immunofluorescence of active caspase-3 (left panel) and 
mean fluorescence value quantification (right panel) in tumor sections. Statistical significance 



















































































Keyword: nanotherapeutic senolysis 
 
A combination of senogenesis (senoinduction with palbociclib) with nanoformulated targeted 
senolysis (encapsulated navitoclax) in triple negative breast cancer (TNBC) is described. Results 
show that treatment of TNBC with palbociclib and further elimination of senescent cells with 
encapsulated navitoclax in galacto-oligosaccharide capped nanoparticles (Gal·NP(Nav)) has 



































































































Nanoparticles synthesis scheme 
 
Figure S1. Schematic representation of the synthesis of loaded Gal·NPs. MCM-41 type scaffolds 
are loaded with ICG or navitoclax (i) and functionalized with APTES (ii). Finally, the beads are 
capped with β(1,4)-hexagalacto-saccharides (iii) to obtain the final Gal·NP. 
 
Materials characterization  
The PXRD of non-calcined nanoparticles (referred as “NPs as synthesized” in Muñoz-Espín et al 
(curve A in Figure S2), showed four low-angle reflections, typical of the hexagonal ordered array 
that can be indexed as (100), (110), (200) and (210) Bragg peaks. The removal of the surfactant 
and the condensation of silanol groups during the calcination step to obtain the starting 
mesoporous silica nanoparticles (starting NPs) are reflected in a slight shift of these peaks 2θ 
values (curve B in Figure S2). For Gal·NP(0) and Gal·NP(ICG) materials (curves C and D in 
Figure S2), the reflections (110) and (200) are lost, most likely due to a reduction of contrast. 
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pore loading and the additional functionalization with the corresponding saccharides did not to a 
large extent modify the mesoporous scaffolding. 
 
Figure S2. Powder X-Ray diffraction patterns at low (left) and high (right) angles of: (a) NPs as 




TEM analysis showed the presence of the mesoporous structure in the final functionalized solids 
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spherical geometry with diameter ca. 100 nm. Moreover, the typical channels of these MSNs 
matrix were visualized as alternate black and white stripes. 
      
 
Figure S3. TEM analysis of: (a) starting NPs, (b) Gal·NP(0) and (c) Gal·NP(ICG). 
 
The N2 adsorption-desorption isotherms of the calcined starting NPs showed two sharp 
adsorption steps (Figure S4A). The first step, at an intermediate P/P0 value (0.1-0.3), is S-6 
typical of this type of materials and attributed to nitrogen condensation inside the mesopores by 
capillarity. The absence of a hysteresis loop in this range and the tight BJH pore distribution 
(inset, Figure S4A), suggested the presence of uniform cylindrical mesopores with pore volume 
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Moreover, the total specific surface was calculated to be 1091.12 m2 g -1 by the application of the 
BET model. On the other hand, N2 adsorption-desorption isotherms of Gal·NP(ICG) and 
Gal·NP(0) showed a significant decrease in the adsorbed N2 volume and surface area  as a 
consequence of the functionalization inside the pores (Figure S4B and S4C). Parameters 
calculated from N2 adsorption-desorption isotherms are listed in Table S1. 
a)   b) 
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Table S1. BET specific surface values, pore volumes and pore sizes calculated from N2 




Pore Volume  
[cm3g-1] 
Pore size  
[nm] 
Starting NPs 1091 0.97 2.79 
Gal·NP(ICG) 57 0.05 -- 
Gal·NP(0) 126 0.1 -- 
 
 
From dynamic light scattering (DLS) measurements (Figure S5, Table S2), the hydrodynamic 
diameter of the starting MSNs and the final nanoparticles was determined, obtaining a single 
population distribution which indicated the good dispersion of the particles. The increase in the 
hydrodynamic diameter between starting NPs and Gal·NP was consistent with the external 











































































Figure S5. Dynamic Light Scattering (DLS) analysis that shows the hydrodynamic diameter of 
starting NPs (black line), Gal·NP(0) (blue line),  Gal·NP(ICG) (red line) and Gal·NP(Nav) (red 
line). 
 
Table S2. Hydrodynamic diameter and zeta potential of selected materials. 
Solid Hydrodynamic particle diameter (nm) Zeta potential (mV) 
Starting NPs 183 ± 8 - 31.2 
Gal·NP(0) 249 ± 6 - 5.6 
Gal·NP(ICG) 376 ± 18 - 13.5 
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Cargo release studies of Gal·NP(ICG) 
4 mg of Gal·NP(ICG)  were suspended in 10mL of water at pH 4.5, stirred and this volume was 
separated into two suspensions of 5mL. Then, aliquots of 300µL were taken and 2µL of NaOH 
(0.15M) were added to each one. The mixtures were vigorously stirred for 3min and they were 
centrifuged for removing the solid. The aliquots were measured by emission spectroscopy to 
obtain the initial point. Then, 5mg of β‐galactosidase from Aspergillus oryzae were added to one 
of the aliquots, and, after certain time 300µL of each suspension were taken, 2µL of NaOH 
(0.15M) were added, centrifuged and cargo released was measured (Figure S6). 
 
Figure S6. β-galactosidase dependent cargo release from Gal·NP(ICG). Nanoparticles were 
suspended in absence (a) or presence (b) of β-galactosidase (4mg Gal·NP(ICG) /10mL water), 
aliquots were taken at different time points, centrifugated to eliminate the nanoparticles and 
fluorescence in the solution measured to quantify cargo released (ICG λem 840 nm). 
 
Gal·NP(ICG) validation in 4T1 cells by flow cytometry 
Control and senescent cells were seeded on 6-multiwell plates at a concentration of 150000 
cells/mL. Next day, a suspension of 1mg/mL Gal·NP(ICG) – previously filtered – was added 
and cells and nanoparticles were incubated together for 6 hours and then washed with PBS in 
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and stained with Hoechst dye. Samples were analysed in the cytometer CytoFLEX S Beckman 
Coulter.   
 
Figure S7. Gal·NP(ICG) released their content more efficiently in palbociclib-senescent cells 
compared to control cells after 6 hours, in concordance with their high levels of β-galactosidase 
activity. 
 
Cell toxicity studies with Gal·NP(0) 
In order to first check the biocompatibility of the synthesized materials (and to be sure that the 
expected cell death after the drug-loaded nanoparticles treatment would be because of the 
navitoclax and no because of the mesoporous container), a 72 hours viability assay was 
performed by treating 4T1 control and senescent cells with capped nanoparticles with no cargo, 
Gal·NP(0). Results showed that the empty Gal-functionalized solid was harmless for the cells at 
several studied concentrations, being the cell viability almost one hundred per cent in all cases 








































































Figure S8. Cell viability assay with non-loaded nanoparticles Gal·NP(0) at different filtered 
concentrations was performed. Control and one week palbociclib treated 4T1 cells were exposed 
for 72 hours to no cargo nanoparticles to see the biocompatibility of the nanodevice. Experiments 
were repeated three times and media ± SEM is represented. 
 
Weight loss in treated mice 
 
Figure S9. Weight loss decreases in Gal·NP(Nav)  treated animals. Weight loss percentages 
expressed as mean ± SEM. 
 
Androgen receptor expression in 4T1 cells 
The 4T1 murine breast cancer cell line was characterized in order to confirm its triple negative 
profile (data not shown). No signal was neither detected for the androgen receptor, which 
confirmed (according to Turner et al) that we were working with a 4T1 population candidate to 








































































Figure S10. Western blot analysis was performed to characterize the molecular profile of the 4T1 
murine breast cancer cells. VCaP cell line was used as positive control for AR marker (expected 
band at 110 kDa). Tubulin was determined as loading control. 
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